RC
KZR

Rangeley Capital’s Kezar Life Sciences KZR Stock Holding History

Rangeley Capital’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.8M Buy
243,073
+157,147
+183% +$1.02M 1.75% 19
2025
Q4 		$540K Buy
+85,926
New +$501K 0.45% 49

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Rangeley Capital's KZR Position: Q1 2026 in Review

Rangeley Capital increased its Kezar Life Sciences (KZR) stake by 183% in Q1 2026, buying an estimated $1.02M and bringing the position to 243,073 shares worth $1.8M. The position accounts for 1.75% of the portfolio, ranked #19.

Rangeley Capital first reported a position in KZR in Q4 2025 and has held it in 2 quarters since. 43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Rangeley Capital held 243,073 shares of Kezar Life Sciences worth $1.8M as of Q1 2026.
  • Rangeley Capital bought 157,147 Kezar Life Sciences shares in Q1 2026, an estimated $1.02M.
  • Kezar Life Sciences made up 1.75% of Rangeley Capital's portfolio in Q1 2026, its #19 holding.
  • Rangeley Capital first reported a position in Kezar Life Sciences in Q4 2025 and has held it in 2 quarters since.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.